Table 2.

KRAS mutation status according to patient and tumour characteristics.

	WT-KRAS (n = 74)	MT-KRAS (n = 75)	P value
Sex
Men (n = 85)	43 (50.6%)	42 (49.4%)	0.46
Women (n = 64)	31 (48.4%)	33 (51.6%)
Age
<50 (n = 17)	9 (53%)	8 (47%)	0.62
50–69 (n = 80)	42 (52.5%)	38 (47.5%)
>69 (n = 52)	23 (44.2%)	29 (55.8%)
Location
Right colon (n = 64)	28 (43.7%)	36 (56.3%)	0.32
Left colon (n = 64)	33 (51.5%)	31 (48.5%)
Rectum (n = 21)	13 (61.9%)	8 (38.1%)
ECOG Index
0 (n = 34)	20 (58.8%)	14 (41.2%)	0.15
1-2 (n = 115)	54 (46.9%)	61 (53.1%)
T stage
T3 (n = 68)	33 (48.5%)	35 (51.5%)	0.46
T4 (n = 81)	41 (50.6%)	40 (49.4%)
N stage
N0 (n = 27)	18 (66.6%)	9 (33.4%)	0.04
N1-2 (n = 122)	56 (45.9%)	66 (54.1%)
Time of diagnostics
Synchronic (n = 77)	36 (46.7%)	41 (53.3%)	0.28
Metachronic (n = 72)	38 (52.8%)	34 (47.2%)
Site of metastases
Peritoneum only (n = 61)	36 (59%)	25 (41%)	0.08
Peritoneum + liver (n = 51)	26 (51%)	25 (49%)
Peritoneum + lung (n = 8)	3 (37.5%)	5 (62.5%)
Multiple (n = 29)	9 (31%)	20 (69%)
Grade of differentiation
Well to moderate (n = 111)	61 (55%)	50 (45%)	0.02
Poor (n = 38)	13 (34.2%)	25 (65.8%)
Histologic type
Classic adenocarcinoma (n = 105)	61 (58%)	43 (42%)	<0.001
Mucinous (n = 44)	12 ((27.7%)	32 (73.8%)
Peritoneal cancer index
1–10 (n = 46)	23 (50%)	23 (50%)	0.15
11–20 (n = 63)	36 (57.1%)	27 (42.9%)
>20 (n = 40)	15 (37.5%)	25 (62.5%)
Primary tumour resection
Yes (n = 130)	69 (53%)	61 (47%)	0.02
No (n = 19)	5 (26.3%)	14 (73.7%)
Chemotherapy treatment
5-FU-based programs plus bevacizumab/cetuximab (n = 103)	57 (55%)	46 (45%)	0.51
5-FU-based programs (n = 46)	17 (37%)	29 (63%)
HIPEC
No (n = 113)	50 (44.2%)	63 (55.8%)	0.01
Yes (n = 36)	24 (66.6%)	12 (33.4%)

A χ2 test was used to calculate the P values.